Literature DB >> 29566368

The Trend of β3-Adrenergic Receptor in the Development of Septic Myocardial Depression: A Lipopolysaccharide-Induced Rat Septic Shock Model.

Ni Yang1, Xiao-Lu Shi2, Bing-Lun Zhang1, Jian Rong1, Tie-Ning Zhang1, Wei Xu1, Chun-Feng Liu1.   

Abstract

Septic shock with low cardiac output is very common in children. However, the mechanism underlying myocardial depression is unclear. The role of β3-AR in the development of myocardial depression in sepsis is unknown. In the present study, we generated an adolescent rat model of hypodynamic septic shock induced by lipopolysaccharide (LPS). Neonatal cardiomyocytes were also treated with LPS to mimic myocardial depression in sepsis, which was confirmed via an in vivo left ventricular hemodynamic study, and measurements of contractility and the Ca2+ transient in isolated adolescent and neonatal cardiomyocytes. After 16 h of LPS treatment, cultured neonatal cardiomyocytes showed a diminished Ca2+ transient amplitude associated with an increase in the β3-AR level. With the addition of a β3-AR agonist, the Ca2+ transient in LPS-treated neonatal rat cardiomyocytes gradually decreased over time; such a change was absent in cells treated with nitric oxide synthase (NOS) inhibitors prior to treatment with a β3-AR agonist. In adolescent rats with septic myocardial depression, cardiac function declined as indicated by decreased MAP, dP/dtmax, and dP/dtmix for 6 h after LPS injection; however, the β3-AR level first increased 2 h after LPS treatment and then decreased 6 h after LPS treatment in the absence of exogenous catecholamines. The results indicate that, in vitro, at the cellular level β3-AR may be involved in the development of myocardial depression (Ca2+ transient depression) in sepsis through NOS signaling pathways; however, in vivo, a complicated mechanism for modulating β3-AR may exist.
© 2018 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Ca2+ transient; Myocardial depression; Rat; Septic shock; β3-Adrenergic receptor

Mesh:

Substances:

Year:  2018        PMID: 29566368      PMCID: PMC5969076          DOI: 10.1159/000487126

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  34 in total

Review 1.  Ejection fraction revisited.

Authors:  J L Robotham; M Takata; M Berman; Y Harasawa
Journal:  Anesthesiology       Date:  1991-01       Impact factor: 7.892

2.  Enhanced inhibition of L-type Ca2+ current by beta3-adrenergic stimulation in failing rat heart.

Authors:  Zhu-Shan Zhang; Heng-Jie Cheng; Katsuya Onishi; Nobuyuki Ohte; Thomas Wannenburg; Che-Ping Cheng
Journal:  J Pharmacol Exp Ther       Date:  2005-08-31       Impact factor: 4.030

3.  Sepsis is associated with an upregulation of functional beta3 adrenoceptors in the myocardium.

Authors:  S Moniotte; C Belge; B Sekkali; P B Massion; B Rozec; C Dessy; J-L Balligand
Journal:  Eur J Heart Fail       Date:  2007-11-19       Impact factor: 15.534

4.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor.

Authors:  An L Moens; Jordan S Leyton-Mange; Xiaolin Niu; Ronghua Yang; Oscar Cingolani; Elisabeth K Arkenbout; Hunter C Champion; Djahida Bedja; Kathleen L Gabrielson; Juan Chen; Yong Xia; Ashley B Hale; Keith M Channon; Marc K Halushka; Norman Barker; Floris L Wuyts; Pawel M Kaminski; Michael S Wolin; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

Review 5.  Cardiac dysfunction in severe sepsis and septic shock.

Authors:  Sergio L Zanotti-Cavazzoni; Steven M Hollenberg
Journal:  Curr Opin Crit Care       Date:  2009-10       Impact factor: 3.687

6.  Coagulopathy, catecholamines, and biomarkers of endothelial damage in experimental human endotoxemia and in patients with severe sepsis: a prospective study.

Authors:  Sisse R Ostrowski; Ronan M G Berg; Nis A Windeløv; Martin A S Meyer; Ronni R Plovsing; Kirsten Møller; Pär I Johansson
Journal:  J Crit Care       Date:  2013-05-31       Impact factor: 3.425

7.  Arterial norepinephrine changes in patients with septic shock.

Authors:  C R Benedict; J A Rose
Journal:  Circ Shock       Date:  1992-11

8.  Left Ventricular Systolic Longitudinal Function as Predictor of Outcome in Patients With Sepsis.

Authors:  Vittorio Palmieri; Francesca Innocenti; Aurelia Guzzo; Elisa Guerrini; Damiano Vignaroli; Riccardo Pini
Journal:  Circ Cardiovasc Imaging       Date:  2015-11       Impact factor: 7.792

9.  Rabbit, a relevant model for the study of cardiac beta 3-adrenoceptors.

Authors:  Leslie Audigane; Benoît-Gilles Kerfant; Aziza El Harchi; Ilka Lorenzen-Schmidt; Gilles Toumaniantz; Anne Cantereau; Daniel Potreau; Flavien Charpentier; Jacques Noireaud; Chantal Gauthier
Journal:  Exp Physiol       Date:  2009-01-16       Impact factor: 2.969

Review 10.  Animal models of sepsis.

Authors:  Mitchell P Fink
Journal:  Virulence       Date:  2013-08-19       Impact factor: 5.882

View more
  4 in total

1.  Identification of circRNA and mRNA expression profiles and functional networks of vascular tissue in lipopolysaccharide-induced sepsis.

Authors:  Mu-Wen Nie; Ye-Chen Han; Zhu-Jun Shen; Hong-Zhi Xie
Journal:  J Cell Mol Med       Date:  2020-05-25       Impact factor: 5.310

Review 2.  The Glucocorticoid Receptor in Cardiovascular Health and Disease.

Authors:  Bing Liu; Tie-Ning Zhang; Jessica K Knight; Julie E Goodwin
Journal:  Cells       Date:  2019-10-09       Impact factor: 6.600

3.  Overexpression of miR-150-5p Alleviates Apoptosis in Sepsis-Induced Myocardial Depression.

Authors:  Xiao Geng Zhu; Tie Ning Zhang; Ri Wen; Chun Feng Liu
Journal:  Biomed Res Int       Date:  2020-08-30       Impact factor: 3.411

4.  Inhibition of micro RNA miR-122-5p prevents lipopolysaccharide-induced myocardial injury by inhibiting oxidative stress, inflammation and apoptosis via targeting GIT1.

Authors:  Wenliang Song; Tiening Zhang; Ni Yang; Tao Zhang; Ri Wen; Chunfeng Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.